Skip to main content
SpringerLink
Log in

Dopamine D4 Receptors

Potential Therapeutic Implications in the Treatment of Schizophrenia

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

In contrast to more traditional antipsychotic drugs such as haloperidol, atypical antipsychotics such as Clozapine are characterised by low levels of extra-pyramidal side effects (EPS) and improved clinical efficacy. This may result from increased binding to dopamine D4 and serotonin 5-HT2A and 5-HT2C receptors concomitant with decreased dopamine D2 receptor blockade, particularly of D2 sites in the striatum where EPS are thought to originate.

Although there is no genetic evidence for a direct role of variation in the D4 receptor gene in schizophrenia, a role for variation in the 5-HT2A receptor gene is supported by genetic and biochemical studies. This does not preclude the D4 receptor as a major therapeutic target for antipsychotic drugs, especially since it is expressed predominantly in the cortex and limbic system, where the antipsychotic effects of drugs such as Clozapine are thought to be mediated.

As novel serotonin-dopamine receptor antagonists with defined pharmacological profiles become available, the careful analysis of the relationship between receptor binding profiles and efficacy will determine the most important receptor targets for improved antipsychotic action without the generation of EPS. Furthermore, the role of D4 receptors as therapeutic targets will soon be determined by the use of selective ligands about to be introduced into clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gottesman II. Schizophrenia genesis. New York: WH Freeman, 1991

    Google Scholar 

  2. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345: 557–62

    Article  PubMed  CAS  Google Scholar 

  3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  4. Carlsson A, Linqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140–4

    Article  CAS  Google Scholar 

  5. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–9

    Article  PubMed  CAS  Google Scholar 

  6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481–3

    Article  PubMed  CAS  Google Scholar 

  7. Andreasen NC. Brain imaging: applications in psychiatry. Science 1988; 239: 1381–8

    Article  PubMed  CAS  Google Scholar 

  8. Zhou QY, Grandy DK, Thambi L, et al. Cloning and expression of human and rat D1 dopamine receptors. Nature 1990; 347: 76–80

    Article  PubMed  CAS  Google Scholar 

  9. Dearry A, Gingrich JA, Falardeau P, et al. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990; 347: 72–6

    Article  PubMed  CAS  Google Scholar 

  10. Sunahara RK, Niznik HB, Weiner DM, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature 1990; 347: 80–3

    Article  PubMed  CAS  Google Scholar 

  11. Monsma FJJ, Mahan LC, McVittie LD, et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A 1990; 87: 6723–7

    Article  PubMed  CAS  Google Scholar 

  12. Bunzow JR, Van Tol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336: 783–7

    Article  PubMed  CAS  Google Scholar 

  13. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–51

    Article  PubMed  CAS  Google Scholar 

  14. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic Clozapine. Nature 1991; 350: 610–4

    Article  PubMed  Google Scholar 

  15. Sunahara RK, Guan HC, O’Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614–9

    Article  PubMed  CAS  Google Scholar 

  16. Tiberi M, Jarvie KR, Silvia C, et al. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1 A receptor. Proc Natl Acad Sci U S A 1991; 88: 7491–5

    Article  PubMed  CAS  Google Scholar 

  17. Giros B, Sokoloff P, Martres MP, et al. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342: 923–6

    Article  PubMed  CAS  Google Scholar 

  18. Monsma FJJ, McVittie LD, Gerfen CR, et al. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989; 342: 926–9

    Article  PubMed  CAS  Google Scholar 

  19. Van Tol HH, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149–52

    Article  PubMed  Google Scholar 

  20. Wong SK, Parker EM, Ross EM. Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem 1990; 265: 6219–24

    PubMed  CAS  Google Scholar 

  21. Lichter JB, Barr CL, Kennedy JL, et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767–73

    Article  PubMed  CAS  Google Scholar 

  22. Matsumoto M, Hidaka K, Tada S, et al. Polymorphic tandem repeats in dopamine D4 receptor are spread over primate species. Biochem Biophys Res Commun 1995; 207: 467–75

    Article  PubMed  CAS  Google Scholar 

  23. Livak KJ, Rogers J, Lichter JB. Variability of dopamine D4 receptor (DRD4) gene sequence within and among nonhuman primate species. Proc Natl Acad Sci USA 1995; 92: 427–31

    Article  PubMed  CAS  Google Scholar 

  24. Makoff AJ. Echoes of D4 receptor repeats [letter]. Nature 1992; 360: 424

    Article  PubMed  CAS  Google Scholar 

  25. Sokoloff P, Andrieux M, Besancon R, et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 1992; 225: 331–7

    Article  PubMed  CAS  Google Scholar 

  26. Sokoloff P, Giros B, Martres MP, et al. Localization and function of the D3 dopamine receptor. Arzneimittel Forschung 1992; 42: 224–30

    PubMed  CAS  Google Scholar 

  27. McAllister G, Knowles MR, Patel S, et al. Characterisation of a chimeric hD3/D2 dopamine receptor expressed in CHO cells. FEBS Lett 1993; 324: 81–6

    Article  PubMed  CAS  Google Scholar 

  28. Seabrook GR, Patel S, Marwood R, et al. Stable expression of human D3 dopamine receptors in GH4Cl pituitary cells. FEBS Lett 1992; 312: 123–6

    Article  PubMed  CAS  Google Scholar 

  29. Freedman SB, Patel S, Marwood R, et al. Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 1994; 268: 417–26

    PubMed  CAS  Google Scholar 

  30. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995; 290: 29–36

    Article  PubMed  CAS  Google Scholar 

  31. Lahti RA, Evans DL, Stratman NC, et al. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993; 236: 483–6

    Article  PubMed  CAS  Google Scholar 

  32. Asghari V, Schoots O, van Kats S, et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994; 46: 364–73

    PubMed  CAS  Google Scholar 

  33. Seeman P, Van Tol HH. Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective. Eur J Pharmacol 1993; 233: 173–4

    Article  PubMed  CAS  Google Scholar 

  34. Mills A, Allet B, Bernard A, et al. Expression and characterization of human D4 dopamine receptors in baculovirus-infected insect cells. FEBS Lett 1993; 320: 130–4

    Article  PubMed  CAS  Google Scholar 

  35. Chabert C, Cavegn C, Bernard A, et al. Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors. J Neurochem 1994; 63: 62–5

    Article  PubMed  CAS  Google Scholar 

  36. Chio CL, Drong RF, Riley DT, et al. D4 dopamine receptor-mediated signalling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269: 11813–9

    PubMed  CAS  Google Scholar 

  37. MacKenzie RG, Van Leeuwen D, Pugsley TA, et al. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol 1994; 266: 79–85

    Article  PubMed  CAS  Google Scholar 

  38. Tice MA, Hashemi T, Taylor LA, et al. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes. Pharmacol Biochem Behav 1994; 49: 567–71

    Article  PubMed  CAS  Google Scholar 

  39. Leysen JE, Gommeren W, Mertens J, et al. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2′-iodospiperone. Psychopharmacology (Berl) 1993; 110: 27–36

    Article  CAS  Google Scholar 

  40. Weinshank RL, Adham N, Macchi M, et al. Molecular cloning and characterization of a high affinity dopamine receptor (D1 beta) and its pseudogene. J Biol Chem 1991; 266: 22427–35

    PubMed  CAS  Google Scholar 

  41. Grandy DK, Zhang YA, Bouvier C, et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci USA 1991; 88: 9175–9

    Article  PubMed  CAS  Google Scholar 

  42. Cox BA, Henningsen RA, Spanoyannis A, et al. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J Neurochem 1992; 59: 627–35

    Article  PubMed  CAS  Google Scholar 

  43. Stormann TM, Gdula DC, Weiner DM, et al. Molecular cloning and expression of a dopamine D2 receptor from human retina. Mol Pharmacol 1990; 37: 1–6

    PubMed  CAS  Google Scholar 

  44. Lahti RA, Figur LM, Piercey MF, et al. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 1992; 42: 432–8

    PubMed  CAS  Google Scholar 

  45. Boundy VA, Luedtke RR, Gallitano AL, et al. Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. J Pharmacol Exp Ther 1993; 264: 1002–11

    PubMed  CAS  Google Scholar 

  46. Grandy DK, Marchionni MA, Makam H, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 1989; 86: 9762–6

    Article  PubMed  CAS  Google Scholar 

  47. Harley EA, Middlemiss DN, Ragan CI. Relationship between inhibition of cyclic AMP production in Chinese hamster ovary cells expressing the rat D2(444) receptor and antagonist/agonist binding ratios. Br J Pharmacol 1995; 115: 1307–13

    Article  PubMed  CAS  Google Scholar 

  48. Seeman P, Guan HC, Civelli O, et al. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 1992; 227: 139–46

    Article  PubMed  CAS  Google Scholar 

  49. Seeman P, Guan HC, Van Tol HH, et al. Low density of dopamine D4 receptors in Parkinson’s, schizophrenia, and control brain striata. Synapse 1993; 14: 247–53

    Article  PubMed  CAS  Google Scholar 

  50. Seeman P, Van Tol HH. Deriving the therapeutic concentrations for Clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 1995; 291: 59–66

    Article  PubMed  CAS  Google Scholar 

  51. Kramer M, Zimbroff D, Last B, et al. The effects of a selective D4 antagonist (1-745,870) in acutely psychotic schizophrenic patients. Psychopharmacol Bull 1996; 32: 467

    Google Scholar 

  52. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, Clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261–84

    PubMed  CAS  Google Scholar 

  53. Brucke T, Roth J, Podreka I, et al. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics [letter]. Lancet 1992; 339: 497

    Article  PubMed  CAS  Google Scholar 

  54. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and Clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538–44

    Article  PubMed  CAS  Google Scholar 

  55. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199–202

    Article  PubMed  CAS  Google Scholar 

  56. Pilowsky LS, Costa DC, Ell PJ, et al. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 1231 IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791–7

    Article  PubMed  CAS  Google Scholar 

  57. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424–8

    Article  PubMed  CAS  Google Scholar 

  58. Meltzer HY. An overview of the mechanism of action of Clozapine. J Clin Psychiatry 1994; 55 Suppl. B: 47–52

    PubMed  Google Scholar 

  59. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992; 13: 116–21

    Article  PubMed  CAS  Google Scholar 

  60. Arranz M, Collier D, Sodhi M, et al. Association between Clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281–2

    Article  PubMed  CAS  Google Scholar 

  61. Sodhi MS, Arranz MJ, Curtis D, et al. Association between Clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169–72

    PubMed  CAS  Google Scholar 

  62. O’Malley KL, Harmon S, Tang L, et al. The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol 1992; 4: 137–46

    PubMed  Google Scholar 

  63. Meador Woodruff JH. Neuroanatomy of dopamine receptor gene expression: potential substrates for neuropsychiatric illness. Clin Neuropharmacol 1995; 18 Suppl. 1: S14–24

    Article  Google Scholar 

  64. Matsumoto M, Hidaka K, Tada S, et al. Full-length cDNA cloning and distribution of human dopamine D4 receptor. Brain Res Mol Brain Res 1995; 29: 157–62

    Article  PubMed  CAS  Google Scholar 

  65. Meador Woodruff JH, Grandy DK, Van Tol HH, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994; 10: 239–48

    PubMed  CAS  Google Scholar 

  66. Matsumoto M, Hidaka K, Tada S, et al. Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum. J Neurochem 1996; 66: 915–9

    Article  PubMed  CAS  Google Scholar 

  67. Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996; 219: 163–6

    Article  PubMed  CAS  Google Scholar 

  68. Schmajuk NA. Animal models for schizophrenia: the hippocampally lesioned animal. Schizophr Bull 1987; 13: 317–27

    Article  PubMed  CAS  Google Scholar 

  69. Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186–91

    PubMed  CAS  Google Scholar 

  70. Mrzljak L, Bergson C, Pappy M, et al. Localization of dopamine D4 receptors in GAB Aergic neurons of primate brain. Nature 1996; 381: 245–8

    Article  PubMed  CAS  Google Scholar 

  71. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441–5

    Article  PubMed  CAS  Google Scholar 

  72. Buckland PR, O’Donovan MC, McGuffin P. Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 1992; 106: 479–83

    Article  CAS  Google Scholar 

  73. Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576–7

    Article  PubMed  CAS  Google Scholar 

  74. Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995; 281: R5–6

    Article  PubMed  CAS  Google Scholar 

  75. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of Clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744–52

    PubMed  CAS  Google Scholar 

  76. Nimgaonkar VL, Wessely S, Tune LE, et al. Response to drugs in schizophrenia: the influence of family history, obstetric complications and ventricular enlargement. Psychol Med 1988; 18: 583–92

    Article  PubMed  CAS  Google Scholar 

  77. Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146: 1307–11

    PubMed  CAS  Google Scholar 

  78. Koreen AR, Lieberman J, Alvir J, et al. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 1994; 51: 132–8

    Article  PubMed  CAS  Google Scholar 

  79. Miller DD, Perry PJ, Cadoret RJ, et al. Effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 8–15

    Article  PubMed  CAS  Google Scholar 

  80. Pickar D, Owen RRJ, Litman RE, et al. Predictors of Clozapine response in schizophrenia. J Clin Psychiatry 1994; 55 Suppl. B: 129–32

    PubMed  Google Scholar 

  81. Catalano M, Nobile M, Novelli E, et al. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol Psychiatry 1993; 34: 459–64

    Article  PubMed  CAS  Google Scholar 

  82. Seeman P, Ulpian C, Chouinard G, et al. Dopamine D4 receptor variant, D4GLYCINE 194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet 1994; 54: 384–90

    Article  PubMed  CAS  Google Scholar 

  83. Nöthen MM, Cichon S, Hemmer S, et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994; 3: 2207–12

    Article  PubMed  Google Scholar 

  84. Petronis A, O’Hara K, Barr CL, et al. (G)n-mononucleotide polymorphism in the human D4 dopamine receptor (DRD4) gene. Hum Genet 1994; 93: 719

    Article  PubMed  CAS  Google Scholar 

  85. Petronis A, Van Tol HH, Kennedy JL. A SmaI PCR-RFLP in the 5′ noncoding region of the human D4 dopamine receptor gene (DRD4). Hum Hered 1994; 44: 58–60

    Article  PubMed  CAS  Google Scholar 

  86. Paterson AD, Ying DJ, Schoots O, et al. A novel RFLP at 5′ non-coding region of dopamine D4 receptor gene (DRD4) is not associated with schizophrenia [abstract]. Psychiatr Genet 1995; 5 Suppl. 1: 57

    Google Scholar 

  87. Cichon S, Nothen MM, Catalano M, et al. Identification of two novel polymorphisms and a rare deletion variant in human dopamine D4 receptor gene. Psychiatr Genet 1995; 5(3): 97–103

    Article  PubMed  CAS  Google Scholar 

  88. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to Clozapine [letter]. Lancet 1993; 341: 116

    Article  PubMed  CAS  Google Scholar 

  89. Kennedy JL, Petronis A, Gao J, et al. Genetic studies of DRD4 and clinical response to neuroleptic medications [abstract]. Am J Hum Genet 1994; 55: 3

    Google Scholar 

  90. Rietschel M, Naber D, Oberlander H, et al. Testing the hypothesis of an association between Clozapine response and allelic association in the dopamine D4 and the serotonin 2A receptor gene [abstract]. Psychiatr Genet 1995; 5 Suppl. 1: 101

    Google Scholar 

  91. Shaikh S, Collier DA, Sham P, et al. Analysis of Clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 1995; 60: 541–5

    Article  PubMed  CAS  Google Scholar 

  92. Shaikh S, Kerwin R, Sham P, et al. D4 polymorphisms in schizophrenic patients treated with Clozapine. Schizophr Res 1995; 15: 165–6

    Article  Google Scholar 

  93. McGuffin P, Asherson P, Owen M, et al. The strength of the genetic effect: is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994; 164: 593–9

    Article  PubMed  CAS  Google Scholar 

  94. Kerwin R, Collier DA. The dopamine D4 receptor and schizophrenia: an update. Psychol Med 1996; 26: 221–7

    Article  PubMed  CAS  Google Scholar 

  95. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxy-tryptamine type 2a receptor gene. Lancet 1996; 347: 1294–6

    PubMed  CAS  Google Scholar 

  96. Benjamin J, Li L, Patterson C, et al. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996; 12: 81–4

    Article  PubMed  CAS  Google Scholar 

  97. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 1996; 12: 78–80

    Article  PubMed  CAS  Google Scholar 

  98. La Hoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121–4

    Google Scholar 

  99. Shaikh S, Gill M, Owen M, et al. Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1994; 54: 8–11

    Article  PubMed  CAS  Google Scholar 

  100. Lim LC, Nothen MM, Korner J, et al. No evidence of association between dopamine D4 receptor variants and bipolar affective disorder. Am J Med Genet 1994; 54: 259–63

    Article  PubMed  CAS  Google Scholar 

  101. Adamson MD, Kennedy J, Petronis A, et al. DRD4 dopamine receptor genotype and CSF monoamine metabolites in Finnish alcoholics and controls. Am J Med Genet 1995; 60: 199–205

    Article  PubMed  CAS  Google Scholar 

  102. Brett PM, Curtis D, Robertson MM, et al. The genetic susceptibility to Gilles de 1a Tourette syndrome in a large multiple affected British kindred: linkage analysis excludes a role for the genes coding for dopamine D1, D2, D3, D4, D5 receptors, dopamine beta hydroxylase, tyrosinase, and tyrosine hydroxylase. Biol Psychiatry 1995; 37: 533–40

    Article  PubMed  CAS  Google Scholar 

  103. Grice DE, Leckman JF, Pauls DL, et al. Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmission-disequilibrium test. Am J Hum Genet 1996; 59: 644–52

    PubMed  CAS  Google Scholar 

  104. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995; 15(1 Suppl. 1): 2–3S

    Article  Google Scholar 

  105. Boyfield I, Brown TH, Coldwell MC, et al. Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists. J Med Chem 1996; 39: 1946–8

    Article  PubMed  CAS  Google Scholar 

  106. Dean B, Hayes W. Decreased cortical serotonin 2A receptors in schizophrenia. Schizophrenia Res 1996; 21: 133–9

    Article  CAS  Google Scholar 

  107. Sodhi MS, Murray RM. Future therapies for schizophrenia. Exp Opin Ther Patents 1997; 7(2): 151–65

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Clinical Psychopharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF, England

    Sanober Shaikh, Andrew Makoff & Robert Kerwin

  2. Section of Molecular Genetics, Department of Psychological Medicine, Institute of Psychiatry, London, England

    Sanober Shaikh & David Collier

Authors
  1. Sanober Shaikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Makoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Collier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Kerwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanober Shaikh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shaikh, S., Makoff, A., Collier, D. et al. Dopamine D4 Receptors. CNS Drugs 8, 1–11 (1997). https://doi.org/10.2165/00023210-199708010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199708010-00001

Keywords

Search

Navigation